World Journal of *Clinical Oncology*

World J Clin Oncol 2021 June 24; 12(6): 393-506





Published by Baishideng Publishing Group Inc

WJC0

World Journal of **Clinical Oncology**

Contents

Monthly Volume 12 Number 6 June 24, 2021

OPINION REVIEW

Health Council of the Netherlands and evaluation of the fifth generation, 5G, for wireless communication 393 and cancer risks

Hardell L

REVIEW

404 Breast cancer: Muscarinic receptors as new targets for tumor therapy

Español A, Salem A, Sanchez Y, Sales ME

MINIREVIEWS

Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase 429 Asghar K, Farooq A, Zulfiqar B, Loya A

437 Imaging diagnosis of bronchogenic carcinoma (the forgotten disease) during times of COVID-19 pandemic: Current and future perspectives

Reddy R

458 Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention

Oneda E, Abeni C, Zanotti L, Zaina E, Bighè S, Zaniboni A

ORIGINAL ARTICLE

Clinical and Translational Research

Impact of community-based exercise program participation on aerobic capacity in women with and 468 without breast cancer

Lee JT, Wagoner CW, Sullivan SA, Amatuli DJ, Nyrop KA, Hanson ED, Stoner L, Jensen BC, Muss HB, Battaglini CL

META-ANALYSIS

482 Phytochemically rich dietary components and the risk of colorectal cancer: A systematic review and metaanalysis of observational studies

Borgas P, Gonzalez G, Veselkov K, Mirnezami R

CASE REPORT

500 Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report

Della Torre S, de Nucci G, Lombardi PM, Grandi S, Manes G, Bollina R



Contents

Monthly Volume 12 Number 6 June 24, 2021

ABOUT COVER

Editorial Board Member of World Journal of Clinical Oncology, Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Acıbadem Bursa Hospital, Fatih Sultan Mehmet Street, Bursa 16059, Turkey. ozkanat@uludag.edu.tr

AIMS AND SCOPE

The primary aim of World Journal of Clinical Oncology (WJCO, World J Clin Oncol) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJCO mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

INDEXING/ABSTRACTING

The WJCO is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; Production Department Director: Yu-Jie Ma; Editorial Office Director: Ze-Man Gong,

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Clinical Oncology	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2218-4333 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
November 10, 2010	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Hiten RH Patel, Stephen Safe	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2218-4333/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
June 24, 2021	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2021 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



WJC0

World Journal of Woriu Journe Clinical Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Clin Oncol 2021 June 24; 12(6): 500-506

DOI: 10.5306/wico.v12.i6.500

ISSN 2218-4333 (online)

CASE REPORT

Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report

Silvia Della Torre, Germana de Nucci, Pietro Maria Lombardi, Samuele Grandi, Gianpiero Manes, Roberto Bollina

ORCID number: Silvia Della Torre 0000-0003-3840-7888; Germana de Nucci 0000-0001-8758-654X; Pietro Maria Lombardi 0000-0002-2633-7977; Samuele Grandi 0000-0002-9570-240X; Gianpiero Manes 0000-0002-5319-588X; Roberto Bollina 0000-0003-0714-9337.

Author contributions: Della Torre S is the guarantor of the article; Lombardi PM contributed to data analysis and interpretation; de Nucci G drafted and revised the article, and issued final approval of the article; Grandi S provided critical revision of the article, and issued final approval of the article; Manes G provided critical revision of the article for important intellectual content, and issued final approval of the article; Bollina R contributed to the drafting of the article, data analysis and interpretation, and final approval of the article; all authors approved the final version of the article, including the authorship list.

Informed consent statement: The patient provided consent to the writing and publication of this case report.

Conflict-of-interest statement: The authors declare that they have no

Silvia Della Torre, Roberto Bollina, Oncology Unit, ASST Rhodense, Rho 20017, Italy

Germana de Nucci, Department of Gastroenterology, Garbagnate Milanese Hospital, ASST Rhodense, Garbagnate Milanese 20024, Italy

Pietro Maria Lombardi, Minimally Invasive Surgery Division, Niguarda Hospital, Milan 20110, Italy

Samuele Grandi, Robotic and Emergency Surgery, General Surgery Division, Manzoni Hospital, Lecco 23900, Italy

Gianpiero Manes, Gastroenterology Unit, ASST Rhodense-Garbagnate Milanese, Garbagnate Milanese 20054, Italy

Corresponding author: Silvia Della Torre, MD, Doctor, Oncology Unit, ASST Rhodense, Corso Europa 2, Rho 20017, Italy. sdellatorre@asst-rhodense.it

Abstract

BACKGROUND

Neuroendocrine gastrointestinal tumors (NETs) are rare and have different natural behaviors. Surgery is the gold standard treatment for local disease while radiotherapy has been demonstrated to be ineffective. Poorly differentiated neuroendocrine carcinomas (NECs) represent only 5%-10% of digestive NETS. Due to aggressive growth and rapid metastatic diffusion, early diagnosis and a multidisciplinary approach are mandatory. The role of surgery and radiotherapy in this setting is still debated, and chemotherapy remains the treatment of choice.

CASE SUMMARY

A 42-year-old male with an ulcerated bleeding rectal lesion was diagnosed with a NEC G3 (Ki67 index > 90%) on May 2015 and initially treated with 3 cycles of first-line chemotherapy, but showed early local progressive disease at 3 mo and underwent sphincter-sparing open anterior low rectal resection. In September 2015, the first post-surgery total-body computed tomography (CT) scan showed an early pelvic disease relapse. Therefore, systemic chemotherapy with FOLFIRI was started and the patient obtained only a partial response. This was followed by pelvic radiotherapy (50 Gy). On April 2016, a CT scan and 18F-fluorodeoxy-



WJCO https://www.wjgnet.com

conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: htt p://creativecommons.org/License s/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Specialty type: Medicine, research and experimental

Country/Territory of origin: Italy

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): 0 Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0

Received: October 23, 2020 Peer-review started: October 23, 2020 First decision: December 4, 2020 Revised: December 24, 2020 Accepted: March 3, 2021 Article in press: March 3, 2021 Published online: June 24, 2021

P-Reviewer: Merkel S S-Editor: Gao CC L-Editor: Webster JR P-Editor: Yuan YY



glucose positron emission tomography imaging showed a complete response (CR) of the pelvic lesion, but pathological abdominal inter-aortocaval lymph nodes were observed. Due to disease progression of abdominal malignant nodes, the patient received radiotherapy at 45 Gy, and finally obtained a CR. As of January 2021, the patient has no symptoms of relapse and no late toxicity after chemotherapy or radiotherapy.

CONCLUSION

This case demonstrates how a multimodal approach can be successful in obtaining long-term CR in metastatic sites in patients with high grade digestive NECs.

Key Words: Neuroendocrine tumor; Multimodal therapy; Rectal carcinoma; Surgery; Radiotherapy; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Neuroendocrine gastrointestinal tumors are rare with different clinical behaviors. Prognostic factors are tumor differentiation, Ki-67 index and the presence of distant metastases. Most of these tumors are well differentiated neuroendocrine tumors with a good prognosis and a 5-year overall survival of 60%-90%. Surgery is the gold standard treatment in local and metastatic disease, while radiotherapy is ineffective. Poorly differentiated neuroendocrine carcinomas represent only 5%-10% of digestive neuroendocrine gastrointestinal tumors. Here we describe the rare case of a patient diagnosed with poorly differentiated rectal metastatic neuroendocrine carcinoma treated with a different treatment approach and with complete remission after 5 years.

Citation: Della Torre S, de Nucci G, Lombardi PM, Grandi S, Manes G, Bollina R. Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report. World J Clin Oncol 2021; 12(6): 500-506 URL: https://www.wjgnet.com/2218-4333/full/v12/i6/500.htm

DOI: https://dx.doi.org/10.5306/wjco.v12.i6.500

INTRODUCTION

Neuroendocrine gastrointestinal tumors (NETs) are rare and have different natural behaviors. Prognostic factors are tumor differentiation, Ki-67 index and the presence of distant metastases. Most of these tumors are well differentiated NETs[1]; even in the presence of metastasis their prognosis is good with a 5-year overall survival (OS) of 60%-90%. Surgery is the gold standard treatment for local disease and often in metastatic cases, while radiotherapy has been demonstrated to be ineffective[2]. Poorly differentiated neuroendocrine carcinomas (NECs) represent only 5%-10% of digestive NETs and among these rectal NECs account for less than 1% of colorectal malignancies. Relative survival at 5 years is 16.3% overall and 57.4%, 56.4%, 26.3%, and 3.0% for stages I, II, III, and IV cancer^[3]. Due to aggressive growth and rapid metastatic diffusion, early diagnosis and a multidisciplinary approach are mandatory. The role of surgery and radiotherapy is still debated, and chemotherapy is the main treatment choice[4]. Based on these data, long-term survivors are rarely described in the literature in the metastatic setting. Here we report a patient with metastatic rectal NEC who maintained a complete response (CR) after 5 years using a different treatment approach.

CASE PRESENTATION

Chief complaints

On May 2015, a 42-year-old male attended our Emergency Department due to acute rectal bleeding.



Della Torre S et al. Neuroendocrine tumor and multimodal therapeutic approach

History of present illness

An urgent colonoscopy showed the presence of an ulcerated lesion 12 cm distant from the anal verge (Figure 1). Endoscopic histological sampling revealed a NEC G3 (Ki67 index > 90%).

History of past illness

He had no previous health problems, only an allergy to nickel.

Personal and family history

No familial history of gastrointestinal disease or tumors.

Physical examination

On presentation, his vital signs were temperature of 36.5°C, pulse rate of 115 bpm, respiratory rate of 17 breaths/min, blood pressure of 110/60 mmHg, and oxygen saturation of 95%. On general physical examination he looked pale. Abdominal examination revealed a non-distended abdomen. Cardiovascular, pulmonary and neurological examinations were unremarkable.

Laboratory examinations

Complete blood count analysis revealed a huge decrease in hemoglobin level (9.8 mg/mL) and decreased iron and ferritin levels (20 µg/mL and 4 µg/mL, respectively).

Imaging examinations

Magnetic resonance imaging (MRI), computed tomography (CT) scan and 18Ffluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) scan confirmed rectal localization with loco-regional lymph node involvement and the absence of metastatic disease. After 3 cycles of first-line chemotherapy with cisplatinum (CDDP 75 mg/m² on day 1, every 3 wk) and etoposide (VP16 100 mg/m² on days 1-3, every 3 wk), local progressive disease was shown by MRI and colonoscopy. Local symptoms rapidly worsened, with pain and bleeding.

MULTIDISCIPLINARY EXPERT CONSULTATION

After a multidisciplinary evaluation, surgery was recommended.

FINAL DIAGNOSIS

The histopathology report confirmed small-cell poorly-differentiated NEC pT3N1 (6/14), G3, Ki67 98%, with negative surgical margins.

TREATMENT

In August 2015, the patient underwent sphincter-sparing open anterior low rectal resection, and fashioning of a colonic terminal stoma.

OUTCOME AND FOLLOW-UP

In September 2015, the first post-surgery total-body CT scan showed early disease relapse with a 85 mm pelvic lesion (Figure 2), without any other disease on 18F-FDG PET/CT. Thus, systemic chemotherapy with FOLFIRI (irinotecan 180 mg/m² on day 1, followed by folinic acid 400 mg/m², a 5-FU bolus of 400 mg/m² and 5-FU 1200 mg/m² in a 44-h infusion days (1-2 cycles every 14 d), was administered, and a partial response (PR) was obtained after 12 cycles. This was followed by pelvic radiotherapy (50 Gy). On April 2016, CT scan and 18F-FDG PET/CT imaging showed CR of the pelvic lesion, but pathological abdominal inter-aortocaval lymph nodes (Figure 3 and 4). Due to early progression after systemic treatment of abdominal malignant nodes, the patient received radiotherapy at 45 Gy and obtained a CR. He was followed-up with CT scan and 18F-FDG PET/CT every 6 mo. At the last follow-up in January 2021






Figure 1 Endoscopic view of rectal neuroendocrine carcinoma.




Figure 2 Computed tomography scan view of rectal neuroendocrine carcinoma.




Figure 3 Computed tomography image of rectal lesion downstaging after chemotherapy.

both examinations confirmed CR in the pelvic and metastatic disease (Figure 5). He had no symptoms and no late toxicity after chemotherapy or radiotherapy.

DISCUSSION

Rectal NECs are rare entities and there is no consensus on their treatment especially local disease^[5]. As there are no guidelines based on prospective studies, oncologists



Della Torre S et al. Neuroendocrine tumor and multimodal therapeutic approach




Figure 4 Positron emission tomography/computed tomography images of periaortic lymph nodes. A: Positron emission tomography image; B: Computed tomography image.




Figure 5 Positron emission tomography/computed tomography images showing complete response after radiotherapy. A: Positron emission tomography image; B: Computed tomography image.

normally use modalities extrapolated from colonic adenocarcinomas or small-cell lung cancer or based on retrospective analysis^[6]. The efficacy of systemic chemotherapy for treating digestive metastatic NEC has been largely demonstrated and the role of radiation therapy (RT) and/or surgery is still debated, both in the early stage and metastatic disease^[7]. Our case highlights several issues related to the possible clinical treatment of rectal NECs, especially how to treat local primary tumors in patients without metastatic disease. Some retrospective studies agree that there are no differences between surgery and chemoradiotherapy in terms of progression-free survival and OS in local rectal NECs, with disease control in approximately 93% of patients treated exclusively with chemoradiotherapy[8]. These results and the knowledge of high risk of metastatic dissemination for NECs suggest that surgery is not indicated. Moreover, if resection is performed, it has been demonstrated that neoadjuvant, pre-surgery or adjuvant chemotherapy administration is associated with improved rates of survival[9]. As in our case, probably resection is justified in the case of symptomatic or relapse disease.

In the metastatic setting, the gold standard first-line treatment is the combination of platinum and etoposide[10]. Even if there is a high response rate (60%) with this schedule, median OS is poor, ranging from 10 mo to 15 mo[11]. The role of second-line treatment is debated. Some schedules have been tested, which have also included irinotecan. The use of this drug is suggested due to its efficacy demonstrated in both small-cell lung cancer and in colorectal cancer in several studies[12]. After surgery, to treat local early disease relapse we used second-line chemotherapy with FOLFIRI, as the efficacy of FOLFIRI has already been demonstrated in a French study of 39 patients who failed etoposide and platinum combination[13-15]. After obtaining a PR with systemic treatment, pelvic RT was performed, with a long-term local CR. Two months after the end of second-line chemotherapy, metastatic disease was identified in intraaortocaval lymph nodes, which showed no response to systemic treatment. The efficacy of radiotherapy in metastatic patients with NECs has been proved in bone and



brain metastasis, but there are no data about its use in other metastatic sites [16,17]. An anecdotal approach with radiosurgery was applied with success in one case of visceral metastasis from rectal MANEC (Mixed Adenoneuroendocrine Carcinoma). Considering the good previous response to radiotherapy, the limited prospects of therapy and the site of oligo-metastasis we decided to treat the patient with another course of RT and obtained a CR.

CONCLUSION

Our case demonstrates how a multimodal approach and continuous follow-up restaging can be successful in obtaining a long-term CR in local and metastatic sites; thus, improving 5-year survival in patients with high grade digestive NEC as confirmed by the last total body CT scan in January 2021 in our patient. Therefore, based on our experience, chemotherapy, RT and surgery should be considered together in the management of rectal NEC even in presence of systemic spread. The treatment for each patient, in the absence of prospective studies and considering the rarity of the disease, need to be accurately tailored.

REFERENCES

- 1 Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P, Maire F, O'Toole D, Lévy P, Sauvanet A, Ruszniewski P. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 2011; 18: 51-59 [PMID: 20959440 DOI: 10.1677/ERC-09-0319]
- Bertani E, Ravizza D, Milione M, Massironi S, Grana CM, Zerini D, Piccioli AN, Spinoglio G, Fazio 2 N. Neuroendocrine neoplasms of rectum: A management update. Cancer Treat Rev 2018; 66: 45-55 [PMID: 29684743 DOI: 10.1016/j.ctrv.2018.04.003]
- Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen AM, 3 Wong WD. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004; 47: 163-169 [PMID: 15043285 DOI: 10.1007/s10350-003-0038-1]
- Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of 4 the colon and rectum: a population-based analysis. Dis Colon Rectum 2015; 58: 294-303 [PMID: 25664707 DOI: 10.1097/DCR.00000000000298]
- 5 Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016; 103: 186-194 [PMID: 26731334 DOI: 10.1159/000443172]
- Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-1355 [PMID: 10604732 DOI: 10.1038/sj.bjc.6690325]
- Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152-160 [PMID: 22967994 DOI: 10.1093/annonc/mds276]
- 8 Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R, Manfredi S, Tougeron D, Desseigne F, Lourenco N, Afchain P, El Hajbi F, Terris B, Rougier P, Coriat R. Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues. Medicine (Baltimore) 2015; 94: e1864 [PMID: 26496341 DOI: 10.1097/MD.000000000001864]
- 9 Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol 2014; 21: 2956-2962 [PMID: 24763982 DOI: 10.1245/s10434-014-3725-3]
- 10 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist 2019; 24: 911-920 [PMID: 30482824 DOI: 10.1634/theoncologist.2018-0382]
- 11 Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107 [PMID: 11571721 DOI: 10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v]
- Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, 12 Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med



2002; 346: 85-91 [PMID: 11784874 DOI: 10.1056/NEJMoa003034]

- Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, 13 Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418 [PMID: 9807987 DOI: 10.1016/S0140-6736(98)02309-5]
- 14 Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, Maire F, Goujon G, Gillet A, Lévy P, Ruszniewski P. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012; 19: 751-757 [PMID: 22940375 DOI: 10.1530/ERC-12-0002]
- Radu EC, Saizu AI, Grigorescu RR, Croitoru AE, Gheorghe C. Metastatic neuroendocrine pancreatic 15 tumor - Case report. J Med Life 2018; 11: 57-61 [PMID: 29696066]
- Zhao Y, Castonguay M, Wilke D, Xu Z, Plourde M, Mulroy L, MacNeil M, Bowes D. Treatment 16 outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. Curr Probl Cancer 2019; 43: 54-65 [PMID: 30107896 DOI: 10.1016/j.currproblcancer.2018.05.006]
- 17 Semrau S, Agaimy A, Pavel M, Lubgan D, Schmidt D, Cavallaro A, Golcher H, Grützmann R, Fietkau R. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report. J Med Case Rep 2019; 13: 82 [PMID: 30902067 DOI: 10.1186/s13256-019-1995-x]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

